Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

NCT02923921 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02923921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02923921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2017
Completion date
March 5, 2020
Enrollment
567 (actual)
Sites
130

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer